top of page

REGENERON WILL BUY BANKRUPT 23ANDME, VOWS ETHICAL USE OF CUSTOMER DNA DATA

  • NEWS Desk Global
  • May 19
  • 1 min read



Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy auction, and promised to prioritize the ethical use of DNA data from customers using ancestry testing and other services.

Through the deal, Tarrytown, New York-based Regeneron aims to bolster its capabilities in genomics-driven drug discovery by integrating 23andMe's trove of more than 15 million customer DNA profiles, collected via its popular direct-to-consumer saliva-testing kits.

Comments

Commenting on this post isn't available anymore. Contact the site owner for more info.
bottom of page